Crushed posaconazole delayed-release tablets for antifungal prophylaxis and treatment in children
Journal of Antimicrobial Chemotherapy · 2024
DOI: 10.1093/jac/dkae373 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2024. Verfasst von Heather Weerdenburg und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Children's Cancer Centre, and General Medicine, The Royal Children's Hospital, Melbourne, Australia. Hauptthemen laut MEDLINE: Triazoles, Antifungal Agents, Tablets, Delayed-Action Preparations. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 13 Literaturangaben.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Objectives
Therapeutic drug monitoring (TDM) is recommended for posaconazole to achieve target concentrations of ≥0.7 mg/L and ≥1.0 mg/L for prophylaxis and treatment of invasive fungal infection (IFI), respectively. However, target attainment is challenging with the oral suspension, particularly in children. Here, we describe our experience using crushed delayed-release tablet (DRT) in a paediatric cohort, with a focus on TDM.
Methods
We undertook a retrospective audit of crushed posaconazole DRT administration via enteral feeding tubes (EFTs) for patients aged ≤18 years over 18 months at The Royal Children’s Hospital Melbourne who had at least one trough concentration measured at steady state. Details of patient demographics, posaconazole dosing, monitoring and adverse effects were recorded.
Results
Twelve patients with a median age of 9 years (range 2 to 14) received posaconazole DRT via EFT for prophylaxis (n = 8) or treatment (n = 4). All children achieved target concentration, with a median dose of 7 mg/kg/day (range 5 to 11) for prophylaxis and 13 mg/kg/day (range 9 to 20) for treatment. The median time to reach therapeutic levels was 7 days (range 5 to 14) for prophylaxis and 20 days (range 15 to 35) for treatment. One child had blockage of their EFT, which was attributed to posaconazole. No other adverse effects were observed.
Conclusions
Crushed posaconazole DRT administered via EFT may be used as a method of attaining therapeutic posaconazole concentrations in children for antifungal prophylaxis and treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Children's Cancer Centre, and General Medicine, The Royal Children's Hospital, Melbourne, Australia.
- Antimicrobials, Clinical Paediatrics and Tropical Diseases Research Group, Murdoch Children's Research Institute, Melbourne, Australia.
- Department of Paediatrics, The University of Melbourne, Melbourne, Australia.
- Department of Infectious Diseases, Peter MacCallum Cancer Centre, Melbourne, Australia.
- Sir Peter MacCallum Department of Oncology, NHMRC National Centre for Infections in Cancer, The University of Melbourne, Melbourne, Australia.
- The Victorian Paediatric Integrated Cancer Service, Victoria State Government, Melbourne, Australia.
ORCID-Profile: Heather Weerdenburg, Joshua Osowicki, Alison Boast
Zitieren
APA
Weerdenburg, H., Gwee, A., Haeusler, G. M., Osowicki, J., & Boast, A. (2024). Crushed posaconazole delayed-release tablets for antifungal prophylaxis and treatment in children. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkae373
Vancouver
Weerdenburg H, Gwee A, Haeusler GM, Osowicki J, Boast A. Crushed posaconazole delayed-release tablets for antifungal prophylaxis and treatment in children. Journal of Antimicrobial Chemotherapy. 2024. doi:10.1093/jac/dkae373
BibTeX
@article{Weerdenburg2024,
author = {Weerdenburg, Heather and Gwee, Amanda and Haeusler, Gabrielle M and Osowicki, Joshua and Boast, Alison},
title = {Crushed posaconazole delayed-release tablets for antifungal prophylaxis and treatment in children},
journal = {Journal of Antimicrobial Chemotherapy},
year = {2024},
doi = {10.1093/jac/dkae373}
}
EUVIMED